Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Verona Pharma Plc ADR shares valued at $1,911,668 were sold by Hahn Mark W on May 29 ’25. At $9.33 per share, Hahn Mark W sold 204,864 shares. The insider’s holdings dropped to 12,678,992 shares worth approximately $1.06 billion following the completion of this transaction.
Also, Hahn Mark W sold 162,704 shares, netting a total of over 1,513,294 in proceeds. Following the sale of shares at $9.30 each, the insider now holds 12,883,856 shares.
Before that, Hahn Mark W had sold 32,432 shares from its account. In a trade valued at $308,983, the Chief Financial Officer traded Verona Pharma Plc ADR shares for $9.53 each. Upon closing the transaction, the insider’s holdings decreased to 32,432 shares, worth approximately $1.1 billion.
As published in their initiating research note from TD Cowen on April 28, 2025, Verona Pharma Plc ADR [VRNA] has been a Buy and the price target has been revised to $100. Analysts at Cantor Fitzgerald started covering the stock with ‘”an Overweight”‘ outlook in a report released in late April. As of January 10, 2025, ROTH MKM has initiated its “Buy” rating for VRNA. Earlier on October 03, 2024, Wells Fargo initiated its rating. Their recommendation was “an Overweight” for VRNA stock.
Analyzing VRNA Stock Performance
During the last five days, there has been a surge of approximately 13.59%. Over the course of the year, Verona Pharma Plc ADR shares have jumped approximately 80.84%. Shares of the company reached a 52-week high of $86.59 on 06/04/25 and a 52-week low of $43.44 on 01/10/25.
Support And Resistance Levels for Verona Pharma Plc ADR (VRNA)
According to the 24-hour chart, there is a support level at 82.88, which, if violated, would cause prices to drop to 81.78. In the upper region, resistance lies at 85.84. The next price resistance is at 87.69. RSI (Relative Strength Index) is 72.16 on the 14-day chart, showing overbought technical sentiment.
